FDA clears B+L presbyopia treatment

Bridge Water, NJ-The FDA has issued a marketing clearance for Bausch + Lomb’s presbyopia treatment, Biotrue ONEday (nesofilcon A) soft (hydrophilic) daily disposable multifocal contact lenses.

The lenses feature Bausch + Lomb’s 3-Zone Progressive design and HyperGel material, which will provide comfortable vision at near, intermediate, and distance throughout the day, the company said.

According to Bausch + Lomb, the HyperGel material meets the oxygen level the eye needs, matches the cornea’s water content, and mimics the lipid layer by using a surfactant-enriched lens surface to retain moisture and shape.

“For people with presbyopia, finding a comfortable daily disposable contact lens that provides clear vision at all distances can be a challenge. The new (lenses) for presbyopia combine the bio-inspired design and benefits that contact lens wearers have come to expect,” said Mark McKenna, vice president and general manager, Vision Care, Bausch + Lomb. “We’re confident that the comfort and clarity that this new lens offers will also be a welcome solution for eye-care professionals.”

In related news, the company also announced the return to the market of Soothe Xtra Protection (XP) eye drops with Restoryl, an emulsion system featuring a proprietary blend of mineral oils and interfacial molecules.

According to Bausch + Lomb, the eye drops target the main source of dry eye symptoms by replenishing the lipid layer of the tear film.

“By restoring lipid layer thickness, (the eye drops) address a key component in the onset of dry eye symptoms. We are pleased to bring back the product to eye care professionals and consumers,” said Cal Roberts, MD, chief medical officer, Bausch + Lomb.

The product is available at Walmart now, and will be available at Target this month.

Further availability is expected over the coming months.

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.